Search Results

You are looking at 161 - 170 of 485 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Uterine Neoplasms

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng

endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract] . 39th Annual Meeting of the Society of Gynecologic Oncologists ; Tampa, FL

Full access

Thymomas and Thymic Carcinomas

David S. Ettinger, Gregory J. Riely, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

for thymoma. 20 , 88 , 89 However, nonanthracycline regimens (eg, cisplatin/etoposide [with or without ifosfamide], carboplatin/paclitaxel) may be useful for patients who cannot tolerate the more aggressive regimens. 89 , 90 For thymic carcinoma, the

Full access

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

update, the NCCN panel added a recommendation for atezolizumab/carboplatin/paclitaxel/bevacizumab (category 1) as first-line therapy for patients with metastatic nonsquamous NSCLC based on results of a recent phase III randomized trial (IMpower150). 78

Full access

Invasive Breast Cancer

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

addition of neoadjuvant trastuzumab to paclitaxel followed by FEC chemotherapy (fluorouracil, epirubicin, and cyclophosphamide) was associated with an increase in the pathologic complete response rate from 26% to 65.2% ( P = .016). 107 Thus, the

Full access

Optimizing Systemic Therapy for Bladder Cancer

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

-positive disease to a regimen of paclitaxel, gemcitabine, and cisplatin (PGC) or observation. 25 The study ultimately showed a survival advantage with adjuvant PGC compared with observation (median not reached [NR] vs 26 months; P <.0009). Unfortunately, the

Full access

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

Laura M. Spring, Yael Bar, and Steven J. Isakoff

(or preceded by) the THP regimen, with docetaxel often substituted by weekly paclitaxel for improved tolerability. The role of anthracyclines in the neoadjuvant treatment of HER2+ breast cancer has been a topic of discussion, given the increasing

Full access

Inflammatory Breast Cancer

Holly Dushkin and Massimo Cristofanilli

with FAC followed by paclitaxel. The pathologic complete response rate was significantly higher in those treated with FAC and paclitaxel (25% vs. 10%). The addition of paclitaxel led to improvement in progression-free (27 vs. 18 months) and median

Full access

Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes

Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park

-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up . Ann Oncol 2020 ; 31 : 1306 – 1319 . 32739407 6. Park SB , Kwok JB , Asher R , Clinical and genetic predictors of paclitaxel neurotoxicity based on

Full access

Treating Triple-Negative Breast Cancer: Where Are We?

Aki Morikawa and Andrew D. Seidman

. Microtubule-Targeting Agents Based on the TNBC subtypes, the basal-like types are postulated to respond well to taxanes because of their expression of proliferation genes. 21 Efficacy of paclitaxel specifically for TNBC (compared with non-TNBC) has been

Full access

Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?

Virginia G. Kaklamani and William J. Gradishar

(standard dose), or a combination of both agents (lapatinib, 1000 mg/d plus standard trastuzumab dosing). 7 The anti-HER2 therapy was administered alone for the first 6 weeks, at which point weekly paclitaxel was added to the assigned anti-HER2 therapy for